Background Most of the current progression of immune checkpoint inhibitors for malignant melanoma is based on data from Caucasians in Western countries, but the benefit of Chinese patients is limited, mainly due to different pathological subtypes. The patients in western countries are mainly skin melanoma (about 90%), while the acral and mucosal types are dominant in China, accounting for 41.8% and 22.6% respectively. Acral and mucosal melanoma have lower response rates to immunotherapy and chemotherapy. Objective Whether immune checkpoint inhibitors can improve the survival of Chinese patients with malignant melanoma, therefore, we conducted a retrospective analysis. Methods We analyzed 53 patients with metastatic melanoma treated in our hospital to evaluate the efficacy and safety of PD‐1 mAb in Chinese patients with metastatic melanoma, and performed univariate and multivariate analyses of prognostic factors that may affect overall survival (OS). Results In a study of 125 patients with advanced malignant melanoma, 53 patients participated, with a median follow‐up of 16 months. Among these, 69.8% died, and 30.2% remained on treatment. Median progression‐free survival (PFS) was 6 months, and median OS was 19 months. Patients treated with immune checkpoint inhibitors had improved outcomes, with a median PFS of 7 months and a median OS of 24 months. Patients with bone metastasis and aberrant Lactate dehydrogenase (LDH) post‐treatment had worse prognoses, while immunotherapy was a protective factor. Subgroup analysis showed the benefits of immunotherapy across various patient characteristics. No unexpected toxicities were observed. Conclusion The study highlights the efficacy of immune checkpoint inhibitors, particularly PD‐1 mAb, in improving survival outcomes for Chinese patients with metastatic melanoma.